Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis

Psoriasis Clinical Trial

Official title:

A Phase 2a, Proof of Concept Study Evaluating the Safety and Tolerability of AX-158 in Patients With Mild to Moderate Plaque Psoriasis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05725057
• Other study ID #: AX-158-1011
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: November 30, 2023
• Est. completion date: December 2024

Study information

• Verified date: March 2024
• Source: Artax Biopharma Inc
• Contact: Suzanne Crowley, MS, BSN
• Phone: 321-266-9347
• Email: ax-158-1011[@]artaxbiopharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Proof of concept study to assess the safety and tolerability of AX-158 in patients with mild to moderate psoriasis. Patients will be evaluated for a 28-day treatment period with either AX-158 or Placebo and then followed for an additional 30 days for safety.

Description:

This is a Phase 2a Proof of Concept randomized, double-blind, placebo-controlled study to investigate the safety and tolerability of AX-158 in patients with mild to moderate Psoriasis. Participants will be randomized 2:1 to receive AX-158 or Placebo. A total of 30 participants will be treated for 28 days and followed for an additional 30 days for safety.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 2024
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Able to understand and willing to provide informed consent and able to comply with the study procedures and restrictions.

2. Diagnosis of plaque psoriasis for =3 months at time of screening.

3. Male or female subjects age 18 to 60 years, inclusive, at the time of informed consent.

4. Body mass index (BMI) 18 to 40 kg/m2, inclusive, where BMI (kg/m2) is calculated by body weight (kg)/height2 (m2).

5. Female subjects may be enroled if the following criteria are met:

1. Documented to be surgically sterile or postmenopausal or practicing true abstinence for at least 28 days prior to investigational product (IP) administration until 30 days (duration of ovulatory cycle) after the last IP administration and having a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours prior to the start of IP administration, or

2. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours prior to the start of IP administration.

3. WOCBP must agree to follow instructions for methods of contraception as described in Appendix 18.2 for the duration of treatment with IP plus 5 half-lives of IP (50 hours) plus 30 days (duration of ovulatory cycle) after the last IP administration.

4. Women must not be pregnant, lactating, breastfeeding, or planning pregnancy during the study period.

6. Male subjects who are sexually active with WOCBP may be enrolled if they are

1. Documented to be surgically sterile (vasectomy), or

2. Practicing true abstinence for 90 days after the last IP administration, or

3. Males who are sexually active with WOCBP must agree to follow instructions for methods of contraception for the duration of treatment with IP plus 5 half-lives of the IP plus 90 days (duration of sperm turnover) after the last IP administration. In addition, male subjects must be willing to refrain from sperm donation during this time.

7. Azoospermic males are exempt from contraceptive requirements. WOCBP who are continuously not heterosexually active are also exempt from contraceptive requirements and must still undergo pregnancy testing as described in inclusion criterion #6b.

8. Fully vaccinated for COVID-19 per local regulations and site standard of care (SOC).

Exclusion Criteria:

1. Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic).

2. Diagnosis of psoriatic arthritis, uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with psoriasis for which a subject requires current systemic (oral, subcutaneous, or intravenous [IV]) (including corticosteroids, immunosuppressants, biologics) immunosuppressant medical treatment. Certain therapies such as non-steroidal anti-inflammatory drugs may be permitted at the discretion of the medical monitor.

3. Psoriasis affecting the scalp only.

4. Inability to tolerate oral medication.

5. A clinically significant history of gastrointestinal disorder likely to influence absorption of IP.

6. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction.

7. Participation in a clinical study and/or receipt of an IP within the previous 3 months or 5 half-lives, whichever is longer, before administration of the first dose of IP.

8. History or evidence of active infection and/or febrile illness within 7 days of first administration of IP.

9. History of serious bacterial, fungal, or viral infections that required hospitalization and IV antibiotic treatment within 90 days prior to screening, or any recent serious infection requiring antibiotic treatment within 30 days of IP administration.

10. Has received a live vaccine within 60 days of first dose of IP.

11. Current clinical radiographic or laboratory evidence of active tuberculosis (TB), or any history of or significant risk for TB.

12. Any major surgery within 4 weeks of IP administration.

13. Has unstable cardiovascular disease, defined as a recent clinical deterioration (eg, unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months.

14. History of malignancy (solid organ or hematologic including myelodysplastic syndrome) or lymphoproliferative disease within the previous 5 years (other than resected cutaneous basal cell or squamous cell carcinoma that has been treated with no evidence of recurrence).

15. Has used topical medications/treatments that could affect psoriasis or sPGA evaluation (including, but not limited to, mild to moderate corticosteroids [eg, hydrocortisone cream, triamcinolone acetonide], calcineurin inhibitor, calcipotriol, salicylic acid/other keratolytic, coal tar, short contact dithranol) within 4 weeks of the first administration of IP.

16. Has received phototherapy that could affect psoriasis or sPGA evaluation (eg, narrowband ultraviolet B [UVB] psoralen [oral or topical] with local UVA) within 4 weeks of the first administration of IP.

17. Has received any systemic non-biologic medications/treatments (including, but not limited to, methotrexate, ciclosporin, acitretin, and apremilast) or any systemic biologic medications/treatments (including, but not limited to etanercept, efalizumab, infliximab, adalimumab, ustekinumab, secukinumab, and ixekizumab) that could affect psoriasis or sPGA evaluation within 4 weeks of the first administration of the IP.

18. Chest X-ray findings suspicious of infection at screening. Subjects may be rescreened and if deemed eligible may be randomized within 28 days of completing an appropriate course of antibiotic treatment for pulmonary infection. If a chest X-ray has been performed within 6 months of the screening visit and the report and results are available, then a chest X-ray is not required at the screening visit.

19. Clinically significant history of previous allergy and/or sensitivity to AX-158 or any of the excipients contained within AX-158.

20. Clinically significant abnormal test results for serum biochemistry, hematology,

and/or urine analyses within 28 days prior to first dose administration of the IP:

1. Leukopenia defined as absolute white blood cell count <3000/mm3 within 28 days of dosing with IP on Day 1.

2. Lymphopenia defined as absolute lymphocyte count <500/mm3 within 28 days of dosing with IP on Day 1.

3. Neutropenia defined as absolute neutrophil count <1000/mm3 within 28 days of dosing with IP on Day 1.

4. Moderate to severe thrombocytopenia defined as platelet count <100,000/mm3 within 28 days of dosing with IP on Day 1.

5. Moderate to severe anemia defined as hemoglobin <9 g/dL within 28 days of dosing with IP on Day 1.

6. Total serum bilirubin, alkaline phosphatase, aspartate transaminase and alanine transaminase >1.5 × upper limit of normal (ULN). If total bilirubin is above the ULN and is then fractionated, direct bilirubin must be within normal limits.

21. Subject with a positive urinary drug screen (including alcohol and cotinine) test results, determined within 28 days before the first dose administration of the IP. A positive test result may be repeated at the investigator's discretion.

22. Clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined within 28 days before first dose of IP including a QRS >120 ms, PR interval >220 ms and QT interval corrected using Fredericia's formula >450 ms.

23. Clinically significant abnormalities in vital signs and physical examination determined within 28 days before first dose of IP.

24. Subjects with a positive COVID-19 test on admission per local regulations and site SOC.

25. Any other condition that, in the investigator's judgement, will substantially increase the risk to the subject if they participate in the study.

Related Conditions & MeSH terms

• Plaque Psoriasis
• Psoriasis

Intervention

Drug:
• AX-158
Subjects randomized to this arm will receive AX-158 treatment for 28 days with a 30 day safety follow-up period.
• Placebo
Subjects randomized to this arm will receive placebo treatment for 28 days with a 30 day safety follow-up period.

Locations

Country	Name	City	State
United Kingdom	Accellacare Northamptonshire	Corby
United Kingdom	Accellacare Warwickshire	Coventry
United Kingdom	Accellacare North London	Northwood
United Kingdom	Accellacare South London	Orpington
United Kingdom	Accellacare Yorkshire	Shipley

Sponsors (1)

Lead Sponsor	Collaborator
Artax Biopharma Inc

Country where clinical trial is conducted

United Kingdom, 

References & Publications (9)

Borroto A, Arellano I, Blanco R, Fuentes M, Orfao A, Dopfer EP, Prouza M, Suchanek M, Schamel WW, Alarcon B. Relevance of Nck-CD3 epsilon interaction for T cell activation in vivo. J Immunol. 2014 Mar 1;192(5):2042-53. doi: 10.4049/jimmunol.1203414. Epub 2014 Jan 27. — View Citation

Borroto A, Arellano I, Dopfer EP, Prouza M, Suchanek M, Fuentes M, Orfao A, Schamel WW, Alarcon B. Nck recruitment to the TCR required for ZAP70 activation during thymic development. J Immunol. 2013 Feb 1;190(3):1103-12. doi: 10.4049/jimmunol.1202055. Epub 2012 Dec 24. — View Citation

Borroto A, Reyes-Garau D, Jimenez MA, Carrasco E, Moreno B, Martinez-Pasamar S, Cortes JR, Perona A, Abia D, Blanco S, Fuentes M, Arellano I, Lobo J, Heidarieh H, Rueda J, Esteve P, Cibrian D, Martinez-Riano A, Mendoza P, Prieto C, Calleja E, Oeste CL, Orfao A, Fresno M, Sanchez-Madrid F, Alcami A, Bovolenta P, Martin P, Villoslada P, Morreale A, Messeguer A, Alarcon B. First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases. Sci Transl Med. 2016 Dec 21;8(370):370ra184. doi: 10.1126/scitranslmed.aaf2140. — View Citation

Gil D, Schamel WW, Montoya M, Sanchez-Madrid F, Alarcon B. Recruitment of Nck by CD3 epsilon reveals a ligand-induced conformational change essential for T cell receptor signaling and synapse formation. Cell. 2002 Jun 28;109(7):901-12. doi: 10.1016/s0092-8674(02)00799-7. — View Citation

Juraske C, Wipa P, Morath A, Hidalgo JV, Hartl FA, Raute K, Oberg HH, Wesch D, Fisch P, Minguet S, Pongcharoen S, Schamel WW. Anti-CD3 Fab Fragments Enhance Tumor Killing by Human gammadelta T Cells Independent of Nck Recruitment to the gammadelta T Cell Antigen Receptor. Front Immunol. 2018 Jul 9;9:1579. doi: 10.3389/fimmu.2018.01579. eCollection 2018. — View Citation

Lettau M, Pieper J, Gerneth A, Lengl-Janssen B, Voss M, Linkermann A, Schmidt H, Gelhaus C, Leippe M, Kabelitz D, Janssen O. The adapter protein Nck: role of individual SH3 and SH2 binding modules for protein interactions in T lymphocytes. Protein Sci. 2010 Apr;19(4):658-69. doi: 10.1002/pro.334. — View Citation

Roy E, Togbe D, Holdorf A, Trubetskoy D, Nabti S, Kublbeck G, Schmitt S, Kopp-Schneider A, Leithauser F, Moller P, Bladt F, Hammerling GJ, Arnold B, Pawson T, Tafuri A. Fine tuning of the threshold of T cell selection by the Nck adapters. J Immunol. 2010 Dec 15;185(12):7518-26. doi: 10.4049/jimmunol.1000008. Epub 2010 Nov 15. — View Citation

Roy E, Togbe D, Holdorf AD, Trubetskoy D, Nabti S, Kublbeck G, Klevenz A, Kopp-Schneider A, Leithauser F, Moller P, Bladt F, Hammerling G, Arnold B, Pawson T, Tafuri A. Nck adaptors are positive regulators of the size and sensitivity of the T-cell repertoire. Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15529-34. doi: 10.1073/pnas.1009743107. Epub 2010 Aug 13. — View Citation

Yiemwattana I, Ngoenkam J, Paensuwan P, Kriangkrai R, Chuenjitkuntaworn B, Pongcharoen S. Essential role of the adaptor protein Nck1 in Jurkat T cell activation and function. Clin Exp Immunol. 2012 Jan;167(1):99-107. doi: 10.1111/j.1365-2249.2011.04494.x. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment-Emergent Adverse Events	The frequency of treatment-emergent adverse events (TEAEs) either started after initial treatment or intensified in severity	Baseline to 28 days of treatment
Secondary	Psoriasis Area and Severity Index (PASI) -25	Proportion of subjects receiving AX-158 compared to placebo with PASI 25	Baseline to 28 days of treatment
Secondary	Psoriasis Area and Severity Index (PASI) -50	Proportion of subjects receiving AX-158 compared to placebo with PASI 50	Baseline to 28 days of treatment
Secondary	Psoriasis Area and Severity Index (PASI) -75	Proportion of subjects receiving AX-158 compared to placebo with PASI 75	Baseline to 28 days of treatment
Secondary	Psoriasis Area and Severity Index (PASI) - 100	Proportion of subjects receiving AX-158 compared to placebo with PASI 100	Baseline to 28 days of treatment
Secondary	Biomarkers	Change from baseline in histological markers of psoriasis in skin biopsies.	Baseline to 28 days of treatment
Secondary	Static Physician Global Assessment (sPGA)	Proportion of patients receiving AX-158 compared to placebo who achieve sPGA score of 0 or 1	Baseline to 28 days of treatment